The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL ...

SAN DIEGO -- Patients with relapsed/refractory mantle cell lymphoma (MCL) lived significantly longer without disease progression with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta ...

PHILADELPHIA – First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer ...

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib–venetoclax and ...

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer Undetectable MRD (uMRD) was assessed by next-generation sequencing at ...

SAN DIEGO — A combination of targeted therapies used for a response-directed duration significantly improved outcomes compared with chemoimmunotherapy for fit patients with untreated chronic ...

VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...

The Inflation Reduction Act (IRA) of 2022 established the ability for the Centers for Medicare and Medicaid Services (CMS) for the first time to negotiate prices for pharmaceutical products. Only a ...